Cancer Therapies

Monoclonal Antibody/Fusion Protein Eradicates erbB-2 Positive Tumors

Published in Monoclonal Antibodies Weekly, May 17th, 2000

Researchers from Canada have developed a recombinant, humanized, single-chain Fv antibody/human interleukin-2 (IL-2) fusion protein for the treatment of tumors overexpressing erbB-2.

"Increased gene copy number of erbB-2 and overexpression of the proto-oncogene product erbB-2 (HER-2/p185) has been reported in 20%-30% of human breast cancers and is associated with decreased time to relapse, increased metastatic properties, and ultimately a decrease in survival time," said R.A. Newberry and colleagues from McMaster University, Canada. "Monoclonal antibodies (MAbs) directed against erbB-2 inhibit the growth of transformed cells that express...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Monoclonal Antibodies Weekly

Source: Monoclonal Antibodies Weekly (2000-05-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry